002727.SZ
Yixintang Pharmaceutical Group Co., Ltd.
SZSE · Healthcare · F 批发零售 · CN
CNY 11.43
−1.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 17.0B | 17.3B | 18.0B | 17.4B | 17.4B |
| Cost of Revenue | 11.4B | 11.7B | 12.3B | 11.6B | 11.3B |
| Gross Profit | 5.6B | 5.7B | 5.7B | 5.7B | 6.1B |
| Operating Expenses | |||||
| R&D Expense | 8.9M | 10.6M | 9.7M | 10.2M | 8.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 439.8M | 446.3M | 466.3M | 428.1M | 440.4M |
| Selling & Marketing Expense | 4.4B | 4.5B | 4.7B | 4.2B | 4.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 5.1B | 5.1B | 5.3B | 4.8B | 4.7B |
| Cost and Expenses | 16.5B | 16.8B | 17.6B | 16.5B | 16.0B |
| Operating Income (EBIT) | 446.1M | 422.4M | 278.0M | 786.4M | 1.2B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 428.4M | 406.6M | 207.3M | 702.6M | 1.2B |
| Income Tax Expense | 143.1M | 134.9M | 97.0M | 142.2M | 222.0M |
| Bottom Line | |||||
| Net Income | 279.2M | 263.4M | 114.1M | 549.4M | 1.0B |
| Earnings from Cont. Ops | 285.3M | 271.7M | 110.3M | 560.4M | 1.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 279.2M | 263.4M | 114.1M | 549.4M | 1.0B |
| Per Share | |||||
| Basic EPS | CN¥0.48 | CN¥0.46 | CN¥0.19 | CN¥0.92 | CN¥1.70 |
| Diluted EPS | CN¥0.48 | CN¥0.46 | CN¥0.19 | CN¥0.92 | CN¥1.70 |
| Revenue Per Share | CN¥29.03 | CN¥30.08 | CN¥30.39 | CN¥29.12 | CN¥29.38 |
| Shares | |||||
| Basic Shares Outstanding | 585.6M | 576.3M | 592.3M | 596.8M | 593.3M |
| Diluted Shares Outstanding | 585.6M | 576.3M | 592.3M | 596.8M | 593.3M |
| Profitability Metrics | |||||
| EBITDA | — | 716.6M | 581.2M | 1.1B | 1.5B |
| D&A | — | 294.2M | 303.2M | 300.6M | 268.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026